Navigation Links
NIH Funds Synedgen to Develop a New Drug to Improve Airway Clearance
Date:9/27/2013

Claremont, CA (PRWEB) September 27, 2013

Synedgen announces the award of a National Heart Lung and Blood Institute (NHLBI) Small Business Innovation Research grant from the NIH to explore the mechanisms of a natural modified biopolymer to both reduce the viscosity of mucus and the cohesion of biofilms, potentially leading to a pulmonary treatment for patients with cystic fibrosis (CF) to enhance airway clearance and augment the activity of standard therapeutic antibiotics. In preliminary studies, this new approach to controlling molecular interactions in thick sputum and biofilms has shown significant reductions in viscosity and cohesion.

Due to a genetic defect, CF patients have thicker mucus in their lungs and respiratory tract that is very difficult to clear. The resulting accumulation of mucus allows for colonization by biofilm-producing bacteria. The combination of thick mucus and invasive bacterial biofilms can dramatically reduce lung function of CF patients. Because the biofilms provide a sheltered environment to protect bacteria from antibiotic treatments, CF patients typically suffer from persistent and recurrent lung infections.

In partnership with Dr. Steven Rowe, Associate Professor School of Medicine, University of Alabama Birmingham (UAB), and Director of the CFF Therapeutics Development Network’s Center for CFTR Detection, researchers will be assessing a new drug’s role in reducing the viscosity of patient derived sputum. Using human bronchial cell lines that have the CF defect, they will study the drug’s effect on the relationship of sputum viscosity and mucociliary clearance by assessing activity on monolayers of ciliated cells. Since the drug has already been shown to disrupt biofilms, studies to examine the combined effect of the drug with standard antibiotic treatments will explore the effects of this new drug in enhancing the antibiotic therapies used in CF patients.

“Our approach is
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. QB3-Industry Biotech Startup Partnership Funds Two Projects
3. German Academic Exchange Service funds international project on spintronics
4. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
5. Express Diagnostics to Raise Funds for American Cancer Society During Blue Earth’s Giant Days Parade
6. Kitware Receives Funds from U.S. Air Force Research Lab to Extend the Bender Toolkit for Anatomical Model Repositioning
7. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
10. Scarred for Life? Synedgen Hopes Not
11. Synedgen's Synoplex® is Headed to the Lewa Wildlife Conservancy in Kenya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Encorium Group, Inc. (Nasdaq: ENCO ), a full service ... for many of the world,s leading pharmaceutical and biotechnology companies, today ... Nasdaq stating that since it had not, as of the date ... June 30, 2009, it was then no longer in compliance with ...
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , , , , ... PPHM ) today announced that it will release its financial results for ... 7:00 a.m. EDT and will host a conference call and webcast to ... , Peregrine,s senior management will discuss financial results for ...
Cached Biology Technology:Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 2Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 3Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:4/17/2014)... Stem cells in bone marrow need to produce hydrogen ... tissue, according to a new study from the Center ... of Dentistry of USC. , Professor Songtao Shi, principal ... sulfide produced by the cells governs the flow of ... cellular signals that results in osteogenesis, or the creation ...
(Date:4/17/2014)... the Amazon help create tinderbox conditions for wildfires ... forest loss during drought years, according to a ... in the Amazon could reach a "tipping point" ... to large-scale loss of trees, making recovery more ... Penn State. , "We documented one of the ...
(Date:4/17/2014)... detected new early-warning signs of the potential loss of ... implications for the diagnosis and treatment of diabetic retinopathy, ... , "We had not expected to see such striking ... Ann Elsner, professor and associate dean in the IU ... "We set out to study the early signs, in ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... at his 4th annual Nutrition & The Eye conference, April ... of Missouri in St. Louis, says molecular medicine is beginning ... other therapies have been exhausted. "These nutritional molecules have ... , cancer research and some human studies", Dr Richer reported. ...
... your carbon footprint frequently include buying compact florescent light bulbs, ... local produce. But how much difference do these actions make? ... California, Berkeley, suggests that who you are and where you ... largest impact. "Everyone has a unique carbon footprint," says ...
... 14, 2011 Novocure today announced that the ... NovoTTF-100A System (NovoTTF) for the treatment of adult ... tumor recurrence after receiving chemotherapy. The portable, ... patients maintain their normal daily activities. The NovoTTF ...
Cached Biology News:Low-cost molecular medicine should be included in modern eye physicians' tool kit 2When it comes to carbon footprints, location and lifestyle matter 2When it comes to carbon footprints, location and lifestyle matter 3When it comes to carbon footprints, location and lifestyle matter 4FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2
WD-repeat protein 4...
... omental preadipocytes are isolated ... healthy donors. There is ... cells. Please inquire for ... also available. Academic discounts ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: